PharmAthene Updates Status Of SparVax Anthrax Vaccine Contract

April 7, 2014 PharmAthene, Inc. announced today that it has received notice from the Department of Health and Human Services (HHS), Biomedical Advanced Research and Development Authority (BARDA), advising the Company of its decision to de-scope the current SparVax® anthrax vaccine contract through a partial termination for convenience.  BARDA will provide additional guidance to PharmAthene on the contractual changes, following which …

Immunovaccine and Pfenex Report Positive Results From Single Dose Anthrax Vaccine Studies

Data demonstrates 100% protection against a lethal anthrax challenge in animals after vaccination with as little as 0.33 microgram of mutant recombinant Protective Antigen; Dose response observed in the first 28 days following vaccination April 1, 2014 Immunovaccine Inc. and Pfenex Inc. today announced positive results from anthrax challenge studies in rabbits using Pfenex’s mutant recombinant Protective Antigen (mrPA) formulated …